Navigation Links
New target for the fight against cancer as a result of excessive blood vessel formation

New blood vessel formation (angiogenesis) stimulates the growth of cancer and other diseases. Anti-angiogenic inhibitors slow down cancer growth by disrupting the blood supply to the tumor. To date, the success of these treatments is limited by resistance, poor efficiency and harmful side effects. In the leading scientific journal Cell, Peter Carmeliet (VIB-KU Leuven) and his team reported that sugar metabolism (a process that we call glycolysis) also plays an essential role in the formation of new blood vessels. These totally revolutionary insights open up many new therapeutic opportunities for the treatment of cancer and diseases as a result of excessive blood vessel formation.

Every growing cell in our body is provided with oxygen and nutrients via our blood vessels.

Blood vessels are formed by endothelial cells which line the inside wall of the vessel. These cells require energy to be able to form new blood vessels. However, it was not known how these cells produced the required energy and it was never considered to inhibit the energy production process in order to block angiogenesis.

Under the guidance of Peter Carmeliet, a team consisting of Katrien De Bock, Maria Georgiadou and Sandra Schoors discovered that glycolysis is the most important mechanism for endothelial cells to supply energy for blood vessel formation. Peter Carmeliet and his team demonstrated that endothelial cells can be paralyzed by blocking glycolysis and consequently stop to form blood vessels. This is the first evidence that starvation of endothelial cells could offer new therapeutic opportunities for the treatment of excessive angiogenesis in diseases (like cancer).

Peter Carmeliet: "Our discovery opens up a whole new domain for inhibition of angiogenesis in various diseases such as cancer. Endothelial cells need nutrients and energy for growth and if you take away their energy, you can prevent them from forming new blood vessels".


Contact: Kris Van der Beken
VIB (the Flanders Institute for Biotechnology)

Related biology technology :

1. BellBrook Labs and Tecan Offer Webinar on Screening Epigenetic Targets
2. Sorrento Therapeutics Presents Preclinical Data of its Fully Human Antibody Programs Targeting Anti-PD-L1 and Anti-PD-1 at the 8th Annual Next Generation Protein Therapeutics Summit
3. Actinium Pharmaceuticals Acute Myeloid Leukemia Clinical Data to be Presented Today at 8th International Symposium on Targeted Alpha Therapy Conference
4. DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks
5. Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets
6. Metabolic Solutions Development Company announces publication of data describing a new drug target for diabetes
7. New Study: Valtrex (Valacyclovir) Side Effects Target the Brain; polyDNA Suggests a Natural Herpes Remedy
8. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
9. Surefire Medical Launches Next Generation Infusion System ST-LT and Specialty Catheters at SIR - Maximizing Targeted Delivery of Embolics Without Reflux
10. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies
11. Targeting T cells in rheumatoid arthritis
Post Your Comments:
(Date:11/25/2015)... 2 nouvelles études permettent d , ... les souches bactériennes retrouvées dans la plaque dentaire ... . Ces recherches  ouvrent une nouvelle voie ... de l,un des problèmes de santé les plus ... --> 2 nouvelles études permettent d , ...
(Date:11/25/2015)... ANGELES and HOLLISTON, Mass. ... Technology, Inc. (Nasdaq: HART ), a biotechnology company ... that CEO Jim McGorry will present at ... December 1, 2015 at 2:30 p.m. PT. The presentation ... below) for 30 days. Management will also be available ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... its business and prospects remain fundamentally strong and ... (zoptarelin doxorubicin) recently received DSMB recommendation to continue ... following review of the final interim efficacy and ... Primary Endpoint in men with heavily pretreated castration- ...
(Date:11/25/2015)... -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today ... discussion at the Piper Jaffray 27th Annual Healthcare Conference ... is scheduled for Wednesday, December 2, at 8:00 a.m. ... will be available for 14 days after the event.  ... Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
Breaking Biology Technology:
(Date:11/11/2015)... 2015   MedNet Solutions , an innovative SaaS-based eClinical ... is pleased to announce that it will be a Sponsor ... event, to be held November 17-19 in Hamburg ... demonstrations of iMedNet , MedNet,s easy-to-use, proven ... has been able to deliver time and cost savings ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:11/9/2015)... Calif. , Nov. 9, 2015  Synaptics Inc. ... interface solutions, today announced broader entry into the automotive ... solutions that match the pace of consumer electronics human ... biometric sensors are ideal for the automotive industry and ... Europe , ...
Breaking Biology News(10 mins):